Clinical trials: Gastroesophageal-junction Cancer
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)
In this study, patients with PD-L1 positive locally advanced patients with resectable gastric cancer or gastroesophageal junction adenocarcinoma were invited to participate in the study.To evaluate the efficacy and safety of…
- Trial name
- NCT05466019
- Testing
- Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the…
- Trial name
- NCT06942767
- Testing
- QLS31905 for Injection, QL2107 Injection, Oxaliplatin Injection
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Gastric Cancer
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
This is a phase I, multi-center clinical trial to evaluate the safety, tolerability, antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with docetaxel in previously-treated locally advanced or…
- Trial name
- NCT05327231
- Testing
- IN10018, Docetaxel
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
This early phase I trial studies the effect of pembrolizumab and lenvatinib in treating patients with gastroesophageal adenocarcinoma that has spread to other places in the body (advanced/metastatic) or cannot be removed by…
- Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT05041153
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the…
- Conditions
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma
- Trial name
- FAST (NCT01630083)
- Testing
- epirubicin, oxaliplatin, capecitabine
- Where
- 48 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 252 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Stomach Cancer, Stomach Neoplasm
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
The primary objective is to evaluate six months survival rate and quality of life at 4 months of ramucirumab alone or in combination with paclitaxel in patients aged 70 years or more who have stomach or GEJ adenocarcinoma and…
- Conditions
- Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- SOCRATE (NCT03760822)
- Testing
- Ramucirumab, Paclitaxel
- Where
- 38 sites in France
- Volunteers
- 112 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Gastric Cancer, Gastroesophageal Junction Cancer
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
The purpose of this study is to collect and evaluate real-world data to enhance understanding of the effectiveness, and treatment patterns of first-line nivolumab treatment in patients with unresectable advanced or metastatic…
- Trial name
- NCT06452329
- Testing
- Nivolumab
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
Validation of a Nutrition Screening Tool
The objective of this study is to evaluate the sensitivity and specificity of two nutrition screening tools to identify inpatients with malnutrition or at risk of malnutrition.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01851928
- Where
- United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06131840
- Testing
- PF-08046050, bevacizumab, 5-Fluorouracil (5-FU)
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 914 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Gastric Carcinoma
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
This multicenter, randomized study will evaluate the efficacy and safety of apatinib compared to docetaxel treatment in patients with advanced gastric cancer.
- Trial name
- NCT02409199
- Testing
- Docetaxel, apatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Zhongshan Hospital
Barrett's Esophagus
Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
The specific aim of this study is to determine the accuracy of Optical Coherence Tomography (OCT) imaging for screening and diagnosis of the distal esophagus in patients undergoing a clinical esophagogastroduodenoscopy (EGD)…
- Trial name
- NCT01401699
- Testing
- Optical Frequency Domain Imaging (OFDI)
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Massachusetts General Hospital
Endometrial Cancer, Cervical Cancer
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Conditions
- Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
- Trial name
- NCT06293898
- Testing
- BL-M07D1
- Where
- 26 sites in United States
- Volunteers
- 280 people
- Sponsor
- SystImmune Inc.
Gastric Cancer, Gastro-oesophageal Junction Cancer
Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer
To explore the clinical value of dynamic detection of circulating tumor cells(CTCs), circulating tumor DNA(ctDNA) and cell-free DNA(cfDNA) in neoadjuvant chemotherapy and operation of resectable or locally advanced gastric or…
- Trial name
- NCT03957564
- Testing
- Neoadjuvant chemotherapy with PSOX regimen., Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma., Detect the tumor related DNA in pathological tissues after operation.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Qinghai University
Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer.
- Trial name
- NCT04014075
- Testing
- Trastuzumab deruxtecan
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 79 people
- Sponsor
- Daiichi Sankyo
Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma
This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia…
- Conditions
- Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Fruquintinib, Ramucirumab
- Trial name
- NCT07144995
- Testing
- Fruquintinib+Paclitaxel, Ramucirumab+Paclitaxel
- Volunteers
- 1,143 people
- Sponsor
- Sun Yat-sen University
Oesophageal Carcinoma
A Study of APR-246 in Oesophageal Cancer
The purpose of this study is to determine whether APR-246, 5-FU and cisplatin are safe and effective in the treatment of platinum resistant oesophageal cancer.
- Trial name
- APROC (NCT02999893)
- Testing
- APR-246
- Where
- 5 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-paclitaxel in the second-line treatment of patients with advanced…
- Trial name
- NCT07139587
- Testing
- Iparomlimab/Tuvonralimab (anti PD-1/CTLA-4) combined with albumin-bound paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingxia Li
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Esophagus Cancer, Esophagogastric Junction Cancer
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients.
- Conditions
- Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation, Targeted Therapy
- Trial name
- NCT04821778
- Testing
- Radiotherapy, Platinum based chemotherapy, Paclitaxel based chemotherapy
- Where
- 5 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences